Accredited InvestorsEmployee ShareholdersInstitutionsPrivate Companies Who We Serve Trading and Investing Data Solutions Private Asset Custody Institutional TradingForge ProTrade private companies with Forge’s institutional brokerage tool​Browse CompaniesIndividual InvestingForge MarketsFind new private company investment opportunities​Forge DataAnalyze private markets via Forge’s intuitive web application​Forge Private Market Index​Monitor a benchmark for actively traded private companies ​Forge Accuidity Private Market Index​Invest in an institutionally-managed diversified basket of private companies (QPs only)​Self-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRASolutions All Insights Private Market Reports Market Insights Buying and Selling Pre-IPO​ All Reports​Private Market UpdatesForge Investment OutlookStartup News and Trends​Private Market Data and Analytics​Tech IPO Calendar for 2024​Private Market Explained​Buying Pre-IPO Shares​Selling Pre-IPO SharesGlossaryVideosFAQsInsights About UsLeadershipInvestor RelationsPeople & CultureCareers About
Log InSign Up
Who We Serve
Solutions
Insights
About
Who We Serve
Solutions
Trading and Investing
Institutional Trading
Individual Investing
Data Solutions
Private Asset Custody
Self-Directed IRA
Insights
Private Market Reports
Market Insights
Buying and Selling Pre-IPO​
About
Log In
Sign Up
Secondary Marketplace / Trade Private Companies / Buy and Sell Ginkgo Bioworks Stock

Ginkgo Bioworks Stock

ginkgobioworks.comHealthcare / BioTech & PharmaFounded: 2008Funding to Date: $785.53MM

Ginkgo Bioworks is the developer of a cell programming platform enabling the growth of biotechnology across diverse markets, from food to fragrance to pharmaceuticals.

Learn more about Ginkgo Bioworks IPO

Register To Buy and Sell Private Company Shares

For more details on financing and valuation of private companies similar to Ginkgo Bioworks before its SPAC, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value

Powered by Forge Data

Access valuation and stock price for companies like Ginkgo Bioworks before its SPAC.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

Ginkgo Bioworks stock FAQs

plusminus

Can you buy Ginkgo Bioworks stock?

You can no longer buy Ginkgo Bioworks stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

How to buy Ginkgo Bioworks stock?

To invest in a private company like Ginkgo Bioworks through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)
  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell Ginkgo Bioworks stock?

You can no longer sell stock of Ginkgo Bioworks on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

How to sell Ginkgo Bioworks stock?

If you hold private company shares of Ginkgo Bioworks - whether as an employee or an early investor - Forge can help you sell them.
  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Ginkgo Bioworks stock on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
plusminus

Is Ginkgo Bioworks a public company?

No, Ginkgo Bioworks is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is Ginkgo Bioworks’ stock price?

The stock price of Ginkgo Bioworks is $1.18 as of 1/18/24.
plusminus

What is Ginkgo Bioworks’ stock ticker symbol?

The ticker symbol of Ginkgo Bioworks is DNA.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Ginkgo Bioworks investors also invested in these private companies

General Atlantic
Y Combinator
Viking Global Investors
T. Rowe Price
Illumina
Bill Gates

Explore private companies in the BioTech & Pharma sector

Colossal Biosciences
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B
Altos Labs
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$6.33B
ADARx Pharmaceuticals
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$827.77MM
Cytonics
Sector
Healthcare / BioTech & Pharma
 
 
AI Therapeutics
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$110MM
Egenesis
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$333.77MM
Apnimed
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$366.58MM
Pendulum Therapeutics
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$308.05MM
Element Biosciences
Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.05B

Team

Management Team

Barry Canton
Co-Founder
Peter Boynton
Chief Commercial Officer
Austin Che
Co-Founder
Ena Cratsenburg
Chief Business Officer
Jason Kelly
Co-Founder, Chief Executive Officer & Board Member
Reshma Shetty
Co-Founder, President & Board Member
Tom Knight
Co-Founder

Board Members

Marjin Dekkers
Christian Henry
Genomeweb 03/14/2022

Ginkgo Bioworks to Acquire Swiss Bioengineering Firm FGen

FGen, a spinout of ETH Zurich, is a contract research organization specializing in strain development and optimization.
Genomeweb 01/19/2022

Ginkgo Bioworks Acquires Massachusetts COVID-19 Testing Firm

Project Beacon COVID-19 was started by F-Prime Capital, GV, and the Broad Institute to help implement COVID-19 testing in Massachusetts and its environs.
Globe Newswire 01/18/2022

FINAL DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Ginkgo Bioworks Holdings, Inc. f/k/a Soaring Eagle Acquisition Corp. Investors to Secure Counsel Before Today’s Important Deadline in Securities Class Action Commenced by the Firm – DNA, SRNG

NEW YORK, Jan. 18, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ginkgo...
Genomeweb 12/13/2021

Eurofins' Clinical Enterprise, Ginkgo Bioworks Partner to Support COVID-19 Testing Program

Operation Expanded Testing Program is designed to provide federally funded COVID-19 testing to children in kindergarten through grade 12, as well as other groups.
Browse More Insights
Trending Companies

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.